SAA has been evaluated as a possible serum biomarker for many tumors including ovarian (Moshkovskii et al.2005; Edgell et al.2010), lung (Sung et al.2011), renal (Sung et al.2011; Tolson et al.2004; Paret et al.2010; Wood et al.2010; Cocco et al.2010), endometrial (Cocco et al.2010), uterine (Cocco et al.2009), and melanoma (Findeisen et al.2009). This evidence concerns the gene SAA2 and melanoma.